Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study

What Was Tested

This clinical trial paper looks at ACTH (Corticotropin) and Cosyntropin.

New therapeutic agents are warranted in idiopathic membranous nephropathy.

The researchers conducted a prospective open label cohort study from 2008 till 2010 (NCT00694863).

Who Took Part

The study group was 15 men.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a open-label and pilot study.

Being open-label, the ACTH (Corticotropin) study did not mask who received what.

It is described as a pilot, a small early test of whether a larger ACTH (Corticotropin) study would be practical.

The timeline in the abstract includes 9 months.

What Was Measured

The primary endpoints concerned the feasibility and incidence of remissions as a primary event.

Secondary endpoints included side effects of treatment and the incidence of remissions and relapses at long-term follow-up.

The subject headings attached to it are Cosyntropin, Cyclophosphamide, Edema, Feasibility Studies, Glomerulonephritis, Membranous, Immunosuppressive Agents and Pilot Projects.

What This Means in Plain Language

The paper is an open-label and pilot study of ACTH (Corticotropin) and Cosyntropin in 15 men over 9 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2015 (PloS one), a journal based in United States.

More context: the ACTH (Corticotropin) compound page and the Cosyntropin compound page, all human trials.